TCG Partner Ken West to Present at Medica in Dusseldorf, November 21, 2019
TCG Partner Ken West will presenting at MEDICA 2019’s MEDICA TECH FORUM, describing a new TCG service for international companies who are thinking of entering the US market.
Rapid 17-Point Assessment for US Market Entry
TCG has developed a 17-point assessment to determine the likely success of new medtech products in the US market. The 17 factors evaluate whether the new product has: well-defined value in the US healthcare system, a path to FDA clearance and acceptable reimbursement, and a cost-effective means to achieve market awareness and rapid product adoption.
TCG’s assessment tool had been developed based on the experience of companies who have been successful (or unsuccessful) in entering the US market.
Mr. West will outline this assessment tool at MEDICA’s TECH FORUM, Thursday November 21 at 13h00.
TCG, a leading transatlantic medtech commercialization and consulting firm, has helped dozens of EU medtech companies enter the US market. To learn how TCG can help you grow your business, call 919-941-0700 or email firstname.lastname@example.org.
Advising Life Science Companies for Growth
Founded in 1998, TCG is an international business consulting firm serving medical device, imaging, diagnostic, digital health and health IT companies from its offices in the USA (Research Triangle Park, North Carolina, San Francisco and San Diego, California) and Europe (Heidelberg, Germany). TCG assists its clients to accelerate their journey to success by providing strategic advisory services across many critical needs: market entry, key opinion leader engagement, product launch, business development, reimbursement and regulatory pathway assessment, distribution channel development, and improving organizational effectiveness. We expand our clients’ reach and company resources by finding new partners and financing sources. We help build new organizations and teams to execute on new opportunities. Our goal is to power our clients’ growth and long-term success.